November 19 2024

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

November 7 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

October 30 2024

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

June 5 2024

Indivior Attends the Office of National Drug Control Policy’s 2024 Opioid Overdose Reversal Medication (OORM) Manufacturers Meeting on June 4, 2024

May 17 2024

Announcing Indivior CARES Community Aid for Recovery, Education and Support

October 4 2023

Indivior Statement on the Availability of OPVEE® (nalmefene) Nasal Spray